Kainos Medicine Inc Cash Flow Conversion Efficiency
Kainos Medicine Inc cash flow conversion efficiency. Based on the latest financial reports, Kainos Medicine Inc (284620) has a cash flow conversion efficiency ratio of -0.551x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.97 Billion ≈ $-2.01 Million USD) by net assets (₩5.40 Billion ≈ $3.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Kainos Medicine Inc (2017–2024)
Cash flow conversion efficiency of Kainos Medicine Inc from 2017 to 2024. This chart illustrates how Kainos Medicine Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 284620 live share price for real-time trading data and today's change.
Kainos Medicine Inc Cash Flow Conversion Ratio Explained
Kainos Medicine Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Kainos Medicine Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kainos Medicine Inc ranked by their cash flow conversion efficiency. Also see Kainos Medicine Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sin-Kung Logistics Berhad
KLSE:0305
|
0.042x |
|
CJ Century Logistics Holdings Bhd
KLSE:7117
|
0.091x |
|
Zungwon En-Sys Inc
KQ:045510
|
0.225x |
|
Times Guaranty Limited
NSE:TIMESGTY
|
-0.017x |
|
SP Systems Co.Ltd
KQ:317830
|
0.010x |
|
Finebesteel
KO:133820
|
0.013x |
|
Canfor Pulp Products Inc.
TO:CFX
|
-0.064x |
|
Orion Digital Corp.
NASDAQ:ORIO
|
0.041x |
Annual Cash Flow Conversion Efficiency for Kainos Medicine Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Kainos Medicine Inc from 2017 to 2024. Review how much free cash does Kainos Medicine Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩1.79 Billion ≈ $1.21 Million |
₩-9.71 Billion ≈ $-6.58 Million |
-5.430x | -348.73% |
| 2023-12-31 | ₩11.75 Billion ≈ $7.96 Million |
₩-14.22 Billion ≈ $-9.64 Million |
-1.210x | -179.71% |
| 2022-12-31 | ₩26.11 Billion ≈ $17.69 Million |
₩-11.30 Billion ≈ $-7.66 Million |
-0.433x | +43.05% |
| 2021-12-31 | ₩12.10 Billion ≈ $8.20 Million |
₩-9.20 Billion ≈ $-6.23 Million |
-0.760x | -23.35% |
| 2020-12-31 | ₩12.35 Billion ≈ $8.37 Million |
₩-7.61 Billion ≈ $-5.16 Million |
-0.616x | -3385.22% |
| 2019-12-31 | ₩9.91 Billion ≈ $6.71 Million |
₩185.74 Million ≈ $125.88K |
0.019x | +937.07% |
| 2018-12-31 | ₩9.83 Billion ≈ $6.66 Million |
₩-22.01 Million ≈ $-14.92K |
-0.002x | +92.18% |
| 2017-12-31 | ₩950.59 Million ≈ $644.20K |
₩-27.23 Million ≈ $-18.45K |
-0.029x | -- |
About Kainos Medicine Inc
Kainos Medicine, Inc. engages in research and development of various medicines for cancers, brain, and infectious diseases in South Korea and internationally. The company's product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson's disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to tre… Read more